March 2024 in “Healthcare” Stem cell treatment improved life quality and sexual function in women with hair loss.
September 2024 in “Egyptian Journal of Dermatology and Venerology” Combining TRA and latanoprost is most effective for treating localized alopecia areata.
17 citations
,
July 2017 in “International Journal of Behavioral Medicine” The Egyptian Arabic Skindex-16 is a reliable way to measure how skin diseases affect quality of life in Egyptian patients.
2 citations
,
April 2025 in “Dermatology and Therapy” Alopecia areata affects quality of life more in adolescents than adults.
3 citations
,
January 2024 in “Annals of Dermatology” The criteria help doctors diagnose and treat alopecia areata more effectively.
October 2021 in “Dermatology Reports” Higher IL-17A levels indicate more severe alopecia areata.
2 citations
,
October 2023 in “Dermatology and therapy” Alopecia areata severely impacts quality of life, causing anxiety, depression, and work impairment.
17 citations
,
January 2013 in “Our Dermatology Online” Dutasteride mesotherapy helps treat male hair loss but may harm sperm and sexual function.
4 citations
,
January 2016 in “Annals of Dermatology” More severe hair loss links to thicker heart fat, suggesting possible heart disease risk.
January 2022 in “Al-Azhar Medical Journal” Higher antigliadin antibody levels are linked to alopecia areata severity.
January 2024 in “Annals of Dermatology” Current treatments for Alopecia Areata don't fully meet patients' needs, indicating a need for better therapies.
October 2025 in “Dermatology Practical & Conceptual” Severe COVID-19 often leads to hair loss in India.
12 citations
,
July 2011 in “European Journal of Dermatology” The VSCAPSI is a helpful method for evaluating the severity of scalp psoriasis.
1 citations
,
July 2023 in “Al-Azhar Medical Journal” Higher antigliadin antibodies are linked to more severe alopecia areata, suggesting screening for celiac disease in these patients.
14 citations
,
January 2020 in “Advances in Dermatology and Allergology” Higher interleukin-15 levels are linked to more severe alopecia areata, but not to age or gender.
April 2021 in “Journal of Investigative Dermatology” Spironolactone safely and effectively treats hair loss in female scarring alopecia patients.
January 2025 in “Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)” Baricitinib is effective and safe for treating severe alopecia areata.
The ProScope HR is an effective, user-friendly, and affordable tool for diagnosing hair loss.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
8 citations
,
October 2018 in “Journal of Investigative Dermatology” Many patients with Alopecia Areata in Korea experience anxiety, depression, and reduced quality of life, which are often unrelated to the severity of hair loss.
14 citations
,
January 2011 in “International Journal of Trichology” Some people with severe, long-lasting baldness responded well to a specific combination treatment.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
11 citations
,
February 2021 in “Journal of Cosmetic Dermatology” Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
1 citations
,
December 2020 in “Dermatology Archives” Systemic steroids temporarily improve severe alopecia areata in children but often lead to relapse.
4 citations
,
October 2024 in “American Journal of Clinical Dermatology” Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
2 citations
,
January 2023 in “Dermatology Practical & Conceptual” AB+ blood group is more common in alopecia areata patients.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.